TRAWS PHARMA INC (TRAW) Stock Price, Forecast & Analysis
NASDAQ:TRAW • US68232V8845
TRAW Key Statistics, Chart & Performance
The current stock price of TRAW is 1.92 USD. In the past month the price increased by 11.63%. In the past year, price decreased by -69.08%.
TRAW Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TRAW. When comparing the yearly performance of all stocks, TRAW is a bad performer in the overall market: 91.69% of all stocks are doing better.
TRAW Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TRAW. While TRAW seems to be doing ok healthwise, there are quite some concerns on its profitability.
TRAW Financial Highlights
Over the last trailing twelve months TRAW reported a non-GAAP Earnings per Share(EPS) of 28.26. The EPS increased by 119.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3282.61% | ||
| ROA | 750.81% | ||
| ROE | 2055.51% | ||
| Debt/Equity | 0 |
TRAW Forecast & Estimates
7 analysts have analysed TRAW and the average price target is 8.16 USD. This implies a price increase of 325% is expected in the next year compared to the current price of 1.92.
For the next year, analysts expect an EPS growth of 99.97% and a revenue growth 1117.39% for TRAW
TRAW Ownership
TRAW Latest News, Press Relases and Analysis
TRAW Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TRAW
Company Profile
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
Company Info
TRAWS PHARMA INC
12 Penns Trail
Newtown PENNSYLVANIA US
Employees: 7
Phone: 12677593680
TRAWS PHARMA INC / TRAW FAQ
What does TRAW do?
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
What is the current price of TRAW stock?
The current stock price of TRAW is 1.92 USD.
Does TRAWS PHARMA INC pay dividends?
TRAW does not pay a dividend.
What is the ChartMill rating of TRAWS PHARMA INC stock?
TRAW has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists TRAW stock?
TRAW stock is listed on the Nasdaq exchange.
What is TRAWS PHARMA INC worth?
TRAWS PHARMA INC (TRAW) has a market capitalization of 15.34M USD. This makes TRAW a Nano Cap stock.